NEOS Investment Management LLC Has $20.44 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

NEOS Investment Management LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 78,431 shares of the medical research company's stock after selling 3,795 shares during the period. NEOS Investment Management LLC's holdings in Amgen were worth $20,442,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Centricity Wealth Management LLC bought a new position in shares of Amgen during the 4th quarter worth about $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen during the third quarter valued at approximately $29,000. Synergy Investment Management LLC acquired a new position in shares of Amgen in the fourth quarter valued at $34,000. Atala Financial Inc bought a new position in Amgen in the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity

In related news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares of the company's stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by company insiders.

Remove Ads

Amgen Stock Up 1.2 %

AMGN traded up $3.62 on Monday, hitting $310.57. 1,017,424 shares of the company were exchanged, compared to its average volume of 3,099,781. The stock's fifty day moving average is $301.08 and its 200-day moving average is $297.94. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The company has a market cap of $166.84 billion, a PE ratio of 41.13, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.07%. Amgen's dividend payout ratio is presently 126.09%.

Analyst Ratings Changes

Several brokerages have recently weighed in on AMGN. UBS Group reiterated a "hold" rating on shares of Amgen in a research report on Wednesday, February 12th. Bank of America upped their price objective on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. StockNews.com raised Amgen from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 price objective on shares of Amgen in a research note on Friday, January 24th. Finally, Johnson Rice set a $294.00 target price on shares of Amgen in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of "Moderate Buy" and an average price target of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.